AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34390504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose thymoglobulin (2.5 mg/kg)
Number of subjects: 120
Study 32107560 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 306
Study 32107560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 35256000 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 35256000 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and independent exercise with a single therapy session
Number of subjects: 72
Study 35256000 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and supervised exercise with three therapy sessions over 12 weeks
Number of subjects: 72
Study 33083903 — intervention group
Group type: EXPERIMENTAL
Intervention: Metasul bearings
Number of subjects: 250
Study 33083903 — intervention group
Group type: COMPARATOR
Intervention: Cerasul bearings
Number of subjects: 250
Study 32586366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose UC-MSCs (3 × 10^6 cells)
Number of subjects: 90
Study 32586366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UC-MSCs (6 × 10^6 cells)
Number of subjects: 90
Study 32586366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32727681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless valve
Number of subjects: 291
Study 32542725 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42
Study 32542725 — intervention group
Group type: COMPARATOR
Intervention: No Connective Tissue Graft (Control)
Number of subjects: 42
Study 35059929 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK surgery
Number of subjects: 348
Study 35059929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline IOP
Number of subjects: 348
Study 35059929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CCT
Number of subjects: 348
Study 34490798 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II malocclusion group
Number of subjects: 252
Study 34490798 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ratio values among malocclusion groups
Number of subjects: 252
Study 35727433 — intervention group
Group type: EXPERIMENTAL
Intervention: high-resolution digital PET (dPET)
Number of subjects: 212
Study 35727433 — intervention group
Group type: COMPARATOR
Intervention: high-resolution conventional PET (cPET)
Number of subjects: 212
Study 34464782 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 80
Study 34464782 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 80
Study 32527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BP target group (140 to < 150 mmHg)
Number of subjects: 105
Study 32527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive BP target group (130 to < 140 mmHg)
Number of subjects: 105
Study 32527283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP target group (< 130 mmHg)
Number of subjects: 105
Study 32527283 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the standard treatment)
Number of subjects: 105
Study 36052462 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisepill electronic monitoring (EM)
Number of subjects: 702
Study 36052462 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report (SR)
Number of subjects: 702
Study 36052462 — intervention group
Group type: COMPARATOR
Intervention: Control arm (Self-report vs Wisepill)
Number of subjects: 702
Study 36052462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 702
Study 34425204 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 38
Study 34425204 — intervention group
Group type: COMPARATOR
Intervention: Elastic tubes training
Number of subjects: 38
Study 35420730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid convergent procedure
Number of subjects: 0
Study 35420730 — intervention group
Group type: COMPARATOR
Intervention: Endocardial catheter ablation
Number of subjects: 0
Study 34700212 — intervention group
Group type: EXPERIMENTAL
Intervention: KarXT (a fixed combination of xanomeline and trospium chloride)
Number of subjects: 148
Study 34700212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 34700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded site-independent PANSS ratings
Number of subjects: 148
Study 33167954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 120
Study 33167954 — intervention group
Group type: COMPARATOR
Intervention: Strip crowns
Number of subjects: 120
Study 36356596 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-rEBUS-GS without fluoroscopy
Number of subjects: 426
Study 36356596 — intervention group
Group type: COMPARATOR
Intervention: VBN-rEBUS-GS with fluoroscopy
Number of subjects: 426
Study 33412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 30 minutes after selatogrel)
Number of subjects: 72
Study 33412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 30 minutes after selatogrel)
Number of subjects: 72
Study 33412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 12 hours after selatogrel)
Number of subjects: 72
Study 33412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 12 hours after selatogrel)
Number of subjects: 72
Study 33412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Ticagrelor (180 mg, 30 minutes after selatogrel)
Number of subjects: 72
Study 33412611 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Clopidogrel (300 or 600 mg, 30 minutes after placebo)
Number of subjects: 72
Study 33412611 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Prasugrel (60 mg, 30 minutes after placebo)
Number of subjects: 72
Study 33412611 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ticagrelor (180 mg, 30 minutes after placebo)
Number of subjects: 72
Study 32364618 — intervention group
Group type: EXPERIMENTAL
Intervention: P+P intervention for 2° Cardiac Arrest group
Number of subjects: 301
Study 32364618 — intervention group
Group type: COMPARATOR
Intervention: 1o No CRT group
Number of subjects: 301
Study 35997854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient SDM
Number of subjects: 52
Study 35997854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient SDM + CHW-navigation
Number of subjects: 52
Study 35997854 — intervention group
Group type: COMPARATOR
Intervention: Comparator (furnishing of LCS decision aid only)
Number of subjects: 52
Study 32356286 — intervention group
Group type: EXPERIMENTAL
Intervention: CORDIS group treatment program (10-week modularized treatment)
Number of subjects: 0
Study 32356286 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32420973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lertal® (nutraceutical)
Number of subjects: 0
Study 32420973 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 35445641 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 701
Study 35445641 — intervention group
Group type: COMPARATOR
Intervention: MCV4-TT
Number of subjects: 701
Study 35445641 — intervention group
Group type: COMPARATOR
Intervention: MenC-TT
Number of subjects: 701
Study 34087690 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure CBM‐I training
Number of subjects: 80
Study 34087690 — intervention group
Group type: COMPARATOR
Intervention: Insecure CBM‐I training
Number of subjects: 80
Study 35358461 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening spinal MRI and pre‐emptive treatment for spinal cord compression
Number of subjects: 0
Study 35358461 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 33741514 — intervention group
Group type: COMPARATOR
Intervention: Collective debriefing (1 debriefing by 6 pairs)
Number of subjects: 44
Study 33741514 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual debriefing (1 debriefing by pair)
Number of subjects: 44
Study 33741514 — intervention group
Group type: COMPARATOR
Intervention: Collective debriefing
Number of subjects: 44
Study 33741514 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual debriefing
Number of subjects: 44
Study 35842575 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 165
Study 35842575 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 165
Study 33792550 — intervention group
Group type: EXPERIMENTAL
Intervention: Patchy-type 12-lead ECG (P-ECG)
Number of subjects: 18
Study 33792550 — intervention group
Group type: COMPARATOR
Intervention: Conventional 12-lead ECG (C-ECG)
Number of subjects: 18
Study 33792550 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ECG
Number of subjects: 18
Study 32306007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pyrotinib (400 mg once daily or 320 mg)
Number of subjects: 72
Study 36434692 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan
Number of subjects: 198
Study 36434692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 33048289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) group
Number of subjects: 210
Study 33048289 — intervention group
Group type: COMPARATOR
Intervention: Non-hemodialysis (non-HD) group
Number of subjects: 210
Study 36498485 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in self-etch (SE) mode
Number of subjects: 22
Study 36498485 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in etch-and-rinse (ER) mode
Number of subjects: 22
Study 36498485 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in selective-enamel-etch (SEE) mode
Number of subjects: 22
Study 36498485 — intervention group
Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL) as control
Number of subjects: 22
Study 33340343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil for suspension (125 mg) under fasted conditions
Number of subjects: 60
Study 33340343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil for suspension (125 mg) under fed conditions
Number of subjects: 60
Study 33340343 — intervention group
Group type: COMPARATOR
Intervention: Granule formulation of cefprozil
Number of subjects: 60
Study 34979962 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-dose furosemide (SF) - continuous infusion of furosemide 100 mg on day 1, with daily incremental doses to 200 mg, 300 mg, and 400 mg.
Number of subjects: 80
Study 34979962 — intervention group
Group type: COMPARATOR
Intervention: Combined diuretics (CD) - combination of oral chlorthalidone 50 mg, spironolactone 50 mg, and infusion of furosemide 100 mg for 4 consecutive days.
Number of subjects: 80
Study 34979962 — intervention group
Group type: COMPARATOR
Intervention: Both SF and CD groups.
Number of subjects: 80
Study 34738551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (24 mg/d intravenously for 1 week)
Number of subjects: 0
Study 34738551 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 32741784 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (TT)
Number of subjects: 30
Study 32741784 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (TT) + Whole body vibration training (WBVT)
Number of subjects: 30
Study 35851689 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) + Amoxicillin (AMX)
Number of subjects: 656
Study 35851689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 32543706 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP6/ABC (1.0 mg/10 mL ABC)
Number of subjects: 20
Study 32543706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL ABC containing excipients)
Number of subjects: 20
Study 36384686 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 105
Study 36384686 — intervention group
Group type: COMPARATOR
Intervention: DuraPrep (0.7% iodophor and 74% isopropyl alcohol)
Number of subjects: 105
Study 36384686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ChloraPrep and DuraPrep
Number of subjects: 105
Study 33176593 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of NMES daily (Group B)
Number of subjects: 76
Study 33176593 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes of NMES daily (Group C)
Number of subjects: 76
Study 33176593 — intervention group
Group type: COMPARATOR
Intervention: No NMES (Group A)
Number of subjects: 76
Study 35710669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar‐Coated Science (SCS)
Number of subjects: 92
Study 35710669 — intervention group
Group type: COMPARATOR
Intervention: Both SCS and DCT
Number of subjects: 92
Study 34380540 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed model
Number of subjects: 40
Study 34380540 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2D diagram
Number of subjects: 40
Study 35580859 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low-calorie diet (800 kcal/day)
Number of subjects: 56
Study 35580859 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 analogue) with habitual activity
Number of subjects: 56
Study 35580859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and placebo
Number of subjects: 56
Study 35580859 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide in combination with exercise training
Number of subjects: 56
Study 35580859 — intervention group
Group type: COMPARATOR
Intervention: Placebo and habitual activity
Number of subjects: 56
Study 34347314 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP modules for assessing comorbidities
Number of subjects: 1000
Study 34347314 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP modules for assessing diabetes
Number of subjects: 1000
Study 34347314 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP modules for assessing hypertension
Number of subjects: 1000
Study 34347314 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP modules for assessing myocardial infarction
Number of subjects: 1000
Study 34347314 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP modules for assessing embolic stroke
Number of subjects: 1000
Study 35006243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 8556
Study 35006243 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 8556
Study 35006243 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment vs non-Hispanic Black
Number of subjects: 8556
Study 35006243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment vs non-Hispanic Black
Number of subjects: 8556
Study 35006243 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment vs Hispanic
Number of subjects: 8556
Study 35006243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment vs Hispanic
Number of subjects: 8556
Study 33828354 — intervention group
Group type: EXPERIMENTAL
Intervention: Criminal Justice (CJ) mandated treatment
Number of subjects: 161
Study 33828354 — intervention group
Group type: COMPARATOR
Intervention: Child Protective Services (CPS) mandated treatment
Number of subjects: 161
Study 33828354 — intervention group
Group type: COMPARATOR
Intervention: Nonmandated treatment
Number of subjects: 161
Study 35149566 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat (an ileal bile acid transporter inhibitor)
Number of subjects: 0
Study 35149566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33750593 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized text messages from pharmacists (SMS group)
Number of subjects: 499
Study 33750593 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 499
Study 32678484 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational questions (Study 1: 4 questions; Study 2: 6 questions)
Number of subjects: 9999
Study 32678484 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational questions (Study 2: 6 questions)
Number of subjects: 9999
Study 32678484 — intervention group
Group type: COMPARATOR
Intervention: No-question control
Number of subjects: 9999
Study 34081249 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Knife Papillotomy (NKP)
Number of subjects: 188
Study 34081249 — intervention group
Group type: COMPARATOR
Intervention: Needle Knife Fistulotomy (NKF)
Number of subjects: 188
Study 34081249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NKP and NKF
Number of subjects: 188
Study 34081249 — intervention group
Group type: EXPERIMENTAL
Intervention: NKP
Number of subjects: 188
Study 34081249 — intervention group
Group type: COMPARATOR
Intervention: NKF
Number of subjects: 188
Study 35186445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75
Study 35186445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75
Study 35186445 — intervention group
Group type: COMPARATOR
Intervention: PTSD+ participants
Number of subjects: 75
Study 35186445 — intervention group
Group type: COMPARATOR
Intervention: PTSD− participants
Number of subjects: 75
Study 35676397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialylated HMOs
Number of subjects: 45
Study 35676397 — intervention group
Group type: COMPARATOR
Intervention: Fucosylated or undecorated HMOs
Number of subjects: 45
Study 33656107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke realistic simulation course
Number of subjects: 17
Study 33656107 — intervention group
Group type: COMPARATOR
Intervention: Neurosonology course
Number of subjects: 17
Study 33656107 — intervention group
Group type: COMPARATOR
Intervention: Emergency Neurologic Life Support (ENLS) course
Number of subjects: 17
Study 32968823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized template for re-interpretation MSK reports
Number of subjects: 1052
Study 36335077 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation (HL) of the inferior mesenteric artery (IMA)
Number of subjects: 196
Study 36335077 — intervention group
Group type: COMPARATOR
Intervention: Low ligation (LL) of the inferior mesenteric artery (IMA)
Number of subjects: 196
Study 34840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy based on the meridian-sinew theory
Number of subjects: 124
Study 34840585 — intervention group
Group type: COMPARATOR
Intervention: Acupotomy based on anatomy
Number of subjects: 124
Study 35839335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) after switching from adalimumab (ADA)
Number of subjects: 225
Study 35839335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) after switching from ustekinumab (UST)
Number of subjects: 225
Study 32103441 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal advance care planning (ACP) program
Number of subjects: 282
Study 32103441 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282
Study 32103441 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-surrogate discussion of care preference
Number of subjects: 282
Study 36346050 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stents (SES)
Number of subjects: 3514
Study 36346050 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy everolimus‐eluting stents (EES)
Number of subjects: 3514
Study 36346050 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stents (ZES)
Number of subjects: 3514
Study 36346050 — intervention group
Group type: EXPERIMENTAL
Intervention: SES in patients with diabetes
Number of subjects: 3514
Study 36346050 — intervention group
Group type: EXPERIMENTAL
Intervention: EES in patients with diabetes
Number of subjects: 3514
Study 36346050 — intervention group
Group type: COMPARATOR
Intervention: ZES in patients with diabetes
Number of subjects: 3514
Study 35987909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabellar botulinum toxin (BTX) injections
Number of subjects: 45
Study 35987909 — intervention group
Group type: COMPARATOR
Intervention: Serial acupuncture (ACU) of the head
Number of subjects: 45
Study 32125188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 83
Study 32125188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 36345180 — intervention group
Group type: EXPERIMENTAL
Intervention: DHS with TSP
Number of subjects: 68
Study 36345180 — intervention group
Group type: COMPARATOR
Intervention: Short PFN
Number of subjects: 68
Study 35074904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1699
Study 35074904 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon-alfa (HDI)
Number of subjects: 1699
Study 35074904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP)
Number of subjects: 1699
Study 35074904 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 1699
Study 34120628 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (knee brace and outpatient physical therapy)
Number of subjects: 128
Study 34120628 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patella stabilizing surgical treatment
Number of subjects: 128
Study 35275531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity following WHO recommendations
Number of subjects: 104
Study 35275531 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry values confirming adherence to WHO recommendations
Number of subjects: 104
Study 35275531 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and accelerometry values in accordance with WHO recommendations
Number of subjects: 104
Study 35275531 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry results
Number of subjects: 104
Study 34481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasomics model
Number of subjects: 193
Study 34481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 193
Study 34481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 193